Search hospitals > Illinois > Chicago
John H. Stroger Jr. Hospital of Cook County
Claim this profileChicago, Illinois 60612
Global Leader in HIV Infection
Global Leader in Human Immunodeficiency Virus Infection
Conducts research for Breast Cancer
Conducts research for AIDS
Conducts research for Lung Cancer
369 reported clinical trials
6 medical researchers
Summary
John H. Stroger Jr. Hospital of Cook County is a medical facility located in Chicago, Illinois. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, Breast Cancer, AIDS, Lung Cancer and other specialties. John H. Stroger Jr. Hospital of Cook County is involved with conducting 369 clinical trials across 513 conditions. There are 6 research doctors associated with this hospital, such as Thomas E. Lad, Paul Rubinstein, MD, Lakshmi Rajdev, and Janardhan Mydam, MD.Area of expertise
1HIV Infection
Global LeaderStage IV
Stage II
Stage III
2Human Immunodeficiency Virus Infection
Global LeaderTop PIs
Thomas E. LadJohn H Stroger Jr Hospital of Cook County2 years of reported clinical research
Expert in Breast Cancer
Expert in Breast cancer
68 reported clinical trials
127 drugs studied
Paul Rubinstein, MDUniversity of Illinois2 years of reported clinical research
Studies Lymphoma
Studies Diffuse Large B-Cell Lymphoma
14 reported clinical trials
35 drugs studied
Lakshmi RajdevSiteman Cancer Center at Washington University10 years of reported clinical research
Studies Anal Cancer
Studies Stomach Cancer
3 reported clinical trials
4 drugs studied
Janardhan Mydam, MDJohn H. Stroger, Jr. Hospital of Cook County8 years of reported clinical research
Studies Premature Birth
Studies Neonatal Death
2 reported clinical trials
4 drugs studied
Clinical Trials running at John H. Stroger Jr. Hospital of Cook County
Lung Cancer
Ovarian Cancer
Breast Cancer
Cancer
Breast cancer
Pancreatic Cancer
Esophageal cancer
Prostate Cancer
Multiple Myeloma
Colorectal Cancer
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at John H. Stroger Jr. Hospital of Cook County?
John H. Stroger Jr. Hospital of Cook County is a medical facility located in Chicago, Illinois. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, Breast Cancer, AIDS, Lung Cancer and other specialties. John H. Stroger Jr. Hospital of Cook County is involved with conducting 369 clinical trials across 513 conditions. There are 6 research doctors associated with this hospital, such as Thomas E. Lad, Paul Rubinstein, MD, Lakshmi Rajdev, and Janardhan Mydam, MD.
Where is John H. Stroger Jr. Hospital of Cook County located?
John H. Stroger Jr. Hospital of Cook County is located at 1969 W Ogden Ave, Chicago, IL. For public transportation, take the Chicago 'L' to the Illinois Medical District station, a short 5-minute walk to the hospital. If driving, directions can be easily found on Waze.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at John H. Stroger Jr. Hospital of Cook County, please contact:
- Financial Assistance Office/Appointment with Financial Counselor: (866) 223-2817
- General Billing & Insurance: (866) 223-2817 or (312) 864-2224
- Paying for Healthcare Services: (312) 864-0200
These contacts are available for assistance with financial assistance applications, billing questions, insurance concerns, and inquiries related to healthcare costs.
What insurance does John H. Stroger Jr. Hospital of Cook County accept?
The John H. Stroger Jr. Hospital of Cook County accepts Medicaid, Medicare, Private Insurance, and Private Pay. They also offer the CareLink financial assistance program for Cook County residents who are uninsured or underinsured, covering a wide range of services including clinic visits, laboratory visits, hospital stays, prescriptions, and urgent and emergency care. To be eligible for CareLink, applicants must reside in Cook County, be uninsured or underinsured, and have an income below 600% of the Federal Poverty Line.
What awards or recognition has John H. Stroger Jr. Hospital of Cook County received?
John H. Stroger Jr. Hospital of Cook County, located in Chicago, Illinois, is recognized by U.S. News & World Report for high performance. It is affiliated with the National Cancer Institute's Minority-Based Community Clinical Oncology Program, offering access to national cooperative clinical trials in cancer treatment, prevention, and control. The hospital also engages in research in HIV, diabetes, and airway control, supported by funding from the National Cancer Institute and the Department of Defense.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.